Rome IV Diagnostic Criteria for Irritable Bowel Syndrome
Also known as: Rome IV IBS, Rome Criteria
The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Rome IV criteria are used in any patient presenting with chronic abdominal pain and altered bowel habits to establish a positive diagnosis of IBS without extensive negative testing. Ideal candidates are young to middle-aged patients (age 20–50) with long-standing symptoms, no alarm features (weight loss, nocturnal pain, gross blood, family history of colorectal cancer), and normal basic investigations (CBC, CRP, TSH). In patients with alarm features, organic disease must first be excluded (colonoscopy, imaging) before confidently applying Rome IV IBS diagnosis. Rome IV criteria are less useful in elderly patients or those with acute-onset severe symptoms, where organic disease is more common.
Strengths & limitations
- Positive diagnostic criterion: Shifts from 'diagnosis of exclusion' to 'diagnosis of inclusion', enabling confident early diagnosis without extensive negative testing.
- Evidence-based subtyping: Four subtypes correlate with distinct pathophysiology, prognosis, and treatment response, enabling targeted therapy.
- High sensitivity and specificity: Studies show Rome IV criteria have >90% positive predictive value when alarm features are absent and basic tests are normal.
- International consensus: Rome Foundation criteria are endorsed by major gastroenterology societies (AGA, ACG, ASGE, ECCO) and enable standardized research and clinical practice.
- Symptom overlap with organic disease: IBS symptoms (abdominal pain, diarrhea) overlap with IBD, celiac disease, and bile acid malabsorption. Careful negative workup is required; Rome criteria alone are insufficient.
- Reliance on patient recall: The 3-month symptom window depends on accurate patient recollection of pain frequency and stool consistency, subject to memory bias and seasonal variation.
- No quantitative severity scale: Rome IV does not grade IBS severity (mild vs. moderate vs. severe); separate instruments (IBS Severity Scoring System, IBS Global Improvement Scale) are needed.
- Subtype variability: About 25% of patients shift between subtypes over time, particularly between IBS-M and IBS-D or IBS-C. Subtype classification may not be stable guides for long-term therapy.
Frequently asked
Does a patient need colonoscopy to diagnose Rome IV IBS?
Not necessarily. If a patient meets Rome IV criteria and lacks alarm features (age <50, no weight loss, no gross blood, negative family history), basic tests (CBC, CMP, CRP, TSH) are sufficient. Colonoscopy is warranted if age ≥50, alarm features present, or if IBS diagnosis remains uncertain after clinical assessment. Negative colonoscopy reassures but is not required for Rome IV diagnosis in low-risk patients.
What if a patient meets Rome IV IBS-D criteria but has elevated fecal calprotectin?
This patient likely does not have IBS; the elevated fecal calprotectin suggests inflammation (IBD, microscopic colitis). Do not apply Rome IV IBS diagnosis. Instead, investigate the elevated marker: consider colonoscopy with biopsies, consider celiac serology, and refer to gastroenterology. Rome IV criteria explicitly require absence of organic disease.
Can I diagnose IBS-D in a patient on loperamide?
No, not reliably. Loperamide artificially improves stool consistency, masking true bowel pattern. Request that the patient discontinue antidiarrheals for 1–2 weeks (if safe) and reassess stool pattern, or calculate Rome IV based on the patient's stool pattern off antidiarrheals. The diagnosis should reflect the underlying disorder, not medication-induced changes.
How is Rome IV IBS different from functional diarrhea or functional constipation?
Rome IV IBS requires both abdominal pain (≥1 day/week) AND stool pattern change. Functional diarrhea (Rome IV) is ≥3 loose stools per week without significant abdominal pain. Functional constipation is <3 stools per week without pain. The presence of pain moves the diagnosis toward IBS; absence of pain suggests functional diarrhea or constipation. This distinction guides therapy (pain-targeted agents vs. symptom-targeted agents).
What if a patient's IBS subtype changes from IBS-C to IBS-D over time?
Subtype shifting occurs in about 25% of IBS patients, particularly between IBS-M and other subtypes. This is normal and reflects the dynamic nature of IBS. Re-assess the patient's stool pattern and adjust therapy accordingly (e.g., discontinue osmotic laxatives if shifting toward IBS-D; add fiber if shifting toward IBS-C). Do not assume subtype is fixed; reassess periodically.
Sources
- Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation. link ↗
How to cite this page
ScholarGate. (2026, June 3). Rome IV Diagnostic Criteria for Irritable Bowel Syndrome. ScholarGate. https://scholargate.app/en/gastroenterology/rome-iv-ibs-criteria
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Gastroparesis Cardinal Symptom IndexGastroenterology↔ compare
- GERD Health-Related Quality of Life ScaleGastroenterology↔ compare
- Patient Assessment of Constipation Quality of LifeGastroenterology↔ compare
- Simple Clinical Colitis Activity IndexGastroenterology↔ compare